The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) hit a new 52-week low and has $35.27 target or 7.00% below today’s $37.92 share price. The 7 months bearish chart indicates high risk for the $90.35B company. The 1-year low was reported on Nov, 23 by Barchart.com. If the $35.27 price target is reached, the company will be worth $6.32 billion less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 544,281 shares traded hands. GlaxoSmithKline plc (ADR) (NYSE:GSK) has declined 11.84% since April 21, 2016 and is downtrending. It has underperformed by 17.17% the S&P500.
Analysts await GlaxoSmithKline plc (ADR) (NYSE:GSK) to report earnings on February, 1. They expect $0.63 earnings per share, up 14.55% or $0.08 from last year’s $0.55 per share. GSK’s profit will be $1.50 billion for 15.05 P/E if the $0.63 EPS becomes a reality. After $0.83 actual earnings per share reported by GlaxoSmithKline plc (ADR) for the previous quarter, Wall Street now forecasts -24.10% negative EPS growth.
GlaxoSmithKline plc (ADR) (NYSE:GSK) Ratings Coverage
Out of 11 analysts covering GlaxoSmithKline (NYSE:GSK), 6 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 55% are positive. $50 is the highest target while $40 is the lowest. The $47.50 average target is 25.26% above today’s ($37.92) stock price. GlaxoSmithKline has been the topic of 16 analyst reports since September 8, 2015 according to StockzIntelligence Inc. On Friday, September 23 the stock rating was initiated by Piperjaffray with “Overweight”. The firm has “Neutral” rating given on Tuesday, September 15 by BNP Paribas. Investec initiated the stock with “Buy” rating in Thursday, October 20 report. The firm earned “Buy” rating on Monday, December 7 by Argus Research. BNP Paribas downgraded the stock to “Underperform” rating in Wednesday, September 14 report. The firm has “Buy” rating given on Wednesday, January 27 by Bryan Garnier & Cie. The firm earned “Hold” rating on Friday, February 26 by Cantor Fitzgerald. The rating was upgraded by Jefferies on Thursday, July 14 to “Buy”. As per Wednesday, December 9, the company rating was upgraded by Bank of America. The stock has “Neutral” rating given by Bank of America on Tuesday, September 8.
According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.”
Another recent and important GlaxoSmithKline plc (ADR) (NYSE:GSK) news was published by Businessfinancenews.com which published an article titled: “GlaxoSmithKline plc (ADR) Earning Release; Here’s What to Expect” on July 26, 2016.
GSK Company Profile
GlaxoSmithKline plc (GSK), incorporated on December 6, 1999, is a healthcare company. The Firm is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company’s divisions include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.